Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Multicenter, Single and Multiple Ascending Dose Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy Followed by an Open-Label Extension

NCT04360434 is registered in ClinicalTrials.gov with Neurimmune AG as lead sponsor.

NCT NCT04360434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04360434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Multicenter, Single and Multiple Ascending Dose Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy Followed by an Open-Label Extension
Lead sponsor
Neurimmune AG
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2020
Completion date
July 26, 2023
Enrollment
46 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid transthyretin cardiomyopathy